Patient-reported Outcomes and Quality of Life in Anemic and Symptomatic Patients With Myelofibrosis: Results From the MOMENTUM Study.

15 , 20 Meanwhile, in patients previously treated with ruxolitinib (SIMPLIFY-2), there was a nominally significant difference in favor of momelotinib versus best available therapy (88.5% ruxolitinib) in MPN-SAF TSS. 16 Because the threshold for superiority for the primary end point (splenic response rate [SRR]) was not met, symptoms could not be formally assessed.

also in 7,732 other papers